65 results
6-K
EX-10.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Current report (foreign)
5:28pm
of the Company for the purpose of selling the Shares of the Company pursuant to this Agreement and the Manager agrees to use its commercially … of the Registration Statement or of any notice objecting to its use or the institution or threatening of any proceeding for that purpose and (v) of the receipt
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
that is composed entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities.
Exemption from … for the production of passive income. For this purpose, cash and cash equivalents are categorized as passive assets. Passive income generally includes
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
into a note payable with a third party for the purpose of financing its Directors and Officers insurance policy. The unsecured loan at inception was $487,500
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Current report (foreign)
4:06pm
the issued Shares of that class.
SUBJECT \* MERGEFORMAT
2.9 For the purpose of Article 2.8(b), all the provisions of these Articles relating to general … :
(a) the Company shall not be treated as a Member for any purpose and shall not exercise any right in respect of the Treasury Shares, and any purported exercise
424B3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Prospectus supplement
4:03pm
” or “S$” refers to the legal currency of Singapore.
“United Kingdom” or “UK” refers to the England, Scotland, Wales and Northern Ireland for the purpose … a single class of shares of Ordinary Shares and all of the then issued shares were re-designated as Ordinary Shares.
Organization Structure and Purpose
F-3
67sf ncjr647pm8pw4k
5 Dec 23
Shelf registration (foreign)
4:06pm
F-3
v1a8dgzfiezsq9 08
5 Dec 23
Shelf registration (foreign)
4:06pm
F-3
EX-23.1
kt19bmd
5 Dec 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
1wyf9byr9 xme
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.3
p89rwlk
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-99.4
og55 ck5qrx5
8 Nov 23
Current report (foreign)
4:11pm
6-K
EX-4.1
okfgojt7 lutcd
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-10.1
g18ibr4juatug
12 Oct 23
Current report (foreign)
8:00am
6-K
EX-10.1
kxcae2x9 2qt8a
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
EX-99.1
ge8qcwj b0nh7bgx5j
4 May 23
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
7:56am
424B3
8yxx38n
31 Mar 23
Prospectus supplement
4:04pm
424B3
26q6dv
2 Dec 22
Prospectus supplement
4:17pm